Prolifaron, Inc.

Prolifaron is engaged in the discovery and early stage development of novel antibody drug therapies through combinatorial antibody library development, proprietary selection technologies, cell-based biological screening, optimization, and animal model development. The privately held Company has leading edge proprietary technologies dedicated to the commercialization of antibodies for therapeutic and diagnostic use. Prolifaron is firmly establishing itself as a leader in innovative antibody technologies.

Activity:

- Research & Development

Product / Technology type(s) covered:

- Bio
- Diagnostics
- Reagents

Therapeutic targets:

Markets Covered

a. HeadQuarter:

b. Continent(s) active:

c. Countries active:

Corporate data:

Number of Employees:

Turnover:

Amount:	Year:	Currency:

Year founded: